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Background: To investigate the impact of physician-assessed late toxicities on patient-reported quality of life (QoL)
for nasopharyngeal carcinoma (NPC) patients with long-term survival.
Methods: A cross-sectional survey of QoL and late toxicities was conducted in 242 NPC patients with disease-free
survival of more than 5 years after treatment. The QoL was assessed by the European Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Late toxicities including neuropathy, hearing loss, dysphagia,
xerostomia, and neck fibrosis were recorded based on the criteria of Common Terminology Criteria for Adverse
Events version 4.0 (CTCAE v.4.0). The general linear model multiple analysis of variance (GLM-MANOVA) was
performed to predict factors associated with the QoL.
Results: In the multifactor model of GLM-MANOVA, of the five late toxicities of CTCAE scales, neuropathy, hearing
loss, and xerostomia were observed to be significantly associated with the overall outcome of the fifteen QLQ-C30
scales. A statistically significant trend (p <0.05) was observed, indicating that NPC survivors with more severe
neuropathy, hearing loss or xerostomia had a worse outcome on global QoL, all five functional scales, and a variety
of symptomatic scales.
Conclusions: To improve QoL outcome for NPC survivors, the development of a modern radiotherapeutic
technique should not only focus on reduction of the dose to the salivary glands, but also on anatomical structures
that are involved in neuropathy and hearing loss.Background
Nasopharyngeal carcinoma (NPC) is a prevalent disease
in Taiwan. With the advent of the treatment technique
of radiotherapy (RT) or a combination of chemotherapy,
NPC patients have a greater chance of living cancer free
for an extended period of time. If the individual organ
receives the radiation dose above the specific dose-
tolerance limit, the so called late complications, which
are usually chronic, irreversible and progressive, would be
induced [1]. Conventionally, assessments of these sequelae
were usually from the physicians’ point of view and
measured according to physical outcome. Several systems
for quantitatively scoring treatment-related toxicities have
been developed and are continuously evolving. The
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unless otherwise stated.for Adverse Events (CTCAE) system is one of the most
widely used tools for documenting toxic effects caused by
cancer treatments in clinical trials [2]. The CTCAE grad-
ing system not only takes into account adverse effects
induced by RT, but also those induced by other treatment
modalities such as chemotherapy or surgery.
In the past decades, quality of life (QoL) and its assess-
ment have become increasingly important in health care.
The concepts of QoL refer to patients’ own perception,
and self-report of their physical, mental, and social func-
tions, as well as other related symptoms [3]. There are
now a variety of well-validated QoL instruments available
for use in the field of oncology. The European Research
and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) is a cancer-specific type of QoL
instrument with good validation and has been widely
used internationally for cancer patients [4].
Growing studies have involved the investigation of QoL
for patients with head and neck cancer (HNC) treated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics (N = 242)
Variables No %
Age, median (range) years 46 (17–78)
≦40 73 30.2






With spouse 188 79.3
Without spouse 49 20.7
Education years
≦6 62 26.2














5 ~ 7 162 66.9
8 ~ 10 54 22.4
11 ~ 13 26 10.7
AJCC: American Joint of Cancer Committee published in 2002; IMRT: intensity
modulated radiotherapy.
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of RT-related late toxicity on the outcome of patients’
QoL [5,6]. In this study, we focused on NPC patients with
long-term survival. We investigated the impact of the
severity of late toxicities, which was graded by physicians
based on CTCAE v.4.0, and on the QoL outcome, which
was patient-reported by using the EORTC QLQ-C30.
Methods
This is a cross-sectional study that adheres to STROBE
guidelines for reporting observational research (Additional
file 1). In total, 242 NPC patients with cancer-free survival
of more than 5 years were enrolled. All of them were
newly diagnosed NPC and treated at the Kaohsiung Chang
Gung Memorial Hospital in Taiwan from January 1997 to
December 2007; those with tumour relapse or second pri-
mary cancers were excluded. As regards the existence of
selection bias, we compared the distributions of sociode-
mographic characteristics (including age, gender, marital
status, and education level) and cancer stage between the
study cohort and the other NPC survivors in the cancer
registration database of the institute, but no statistically
significant differences were found. The Medical Ethics and
the Human Clinical Trial Committee at Chang Gung
Memorial Hospital in Taiwan has approved the study (No.
103-1495B) and informed consent was obtained from all
eligible patients. One hundred of the patients were treated
with intensity-modulated RT (IMRT) and the others using
non-IMRT, which included 2-dimensional RT (2DRT, n =
39), 3-dimensional conformal RT (3DCRT, n = 24), and
2DRT plus boost by 3DCRT (n = 79) at different time pe-
riods. The detailed procedures of these techniques have
been described in our previous publication [7]. Table 1
lists the distributions of patient characteristics including
age, gender, marital status, education years, cancer stage,
RT technique, chemotherapy, and survival years at the
point of investigation. Cancer stage was recorded ac-
cording to the American Joint Cancer Committee
(AJCC) staging system, published in 2002. Five items
of late toxicities, including neuropathy, hearing loss,
dysphagia, xerostomia, and neck fibrosis, which are rou-
tinely assessed by physicians for NPC survivors in our
clinical practice, were recorded based on CTCAE v.4.
The EORTC QLQ-C30 version 3.0 was used to assess
the cancer-specific QoL status. The questionnaires have
been tested in Taiwanese NPC patients and excellent reli-
ability and validity were obtained [8]. EORTC QLQ-C30
incorporates a range of QoL issues that are relevant to a
broad range of cancer patients and contains a global QoL
scale, five functional scales (physical, role, cognitive, emo-
tional, and social), three symptom scales (fatigue, pain,
and nausea/vomiting), and six single items (dyspnoea, in-
somnia, appetite loss, constipation, diarrhoea, and finan-
cial difficulties). All scales pertaining to the QLQ-C30range from 0 to 100. A higher score for global QoL or a
functional scale indicates a relatively better level of glo-
bal QoL or functioning, whereas a higher score for a
symptom scale denotes greater severity of a symptom or
problem(s) [4].
The mean scores of the QoL scales were calculated ac-
cording to the EORTC QLQ scoring manual [9]. To deal
with the missing data, the missing items were assumed
to have values equal to the average of those items that
were present for the respondents, if at least half of the
items from the scale have been answered. For the miss-
ing form, the mean imputation was used to replace the
missing data in each scale.To analyse the predictive vari-
ables associated with and the QoL scales, the general linear
model multivariate analysis of variance (GLM-MANOVA)
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factor model of GLM-MANOVA were entered as inde-
pendent variables into the multi-factor model (backward
exclusion) [6]. Wilk’s λ was used to test the impact of each
variable included in the model. In case of a significant asso-
ciation between a factor and all QoL scales taken together,
a second ANOVA was performed to investigate the associ-
ation between that prognostic factor and each QoL scale
separately, with post-hoc testing using the Bonferroni
method. A 10-point difference of the mean scores of QoL
data between groups was considered clinically significant,
and the effect sizes of the difference were further measured
by calculating the Cohen’s D coefficient. Effect sizes of
<0.50, 0.50–0.79, and ≥0.80 were regarded as small, moder-
ate, and large, respectively [10].
Results
Outcomes of QoL and late toxicities
The calculated scores for the QLQ-C30 are shown in
Table 2. The mean score for global quality of life was
56.7. The mean scores of the five functional scales
ranged from 77.0 to 89.1, with physical and role func-
tioning scoring higher than others. Fatigue, followed by
insomnia and financial problems were the top three
symptomatic problems. Concerning symptomatic late
toxicities (≧ grade 2), the respective distributions were
32 (13.2%) in neuropathy, 123 (50.8%) in hearing loss, 98
(40.5%) in dysphagia, 135 (55.8%) in xerostomia, and 65
(26.9%) in neck fibrosis (Table 3). Among them, fifty
(20.6%) survivors required a hearing aid because theirTable 2 Scores of EORTC QLQ-C30 for survivors of
nasopharyngeal carcinoma
Scales Mean (SD) Median Range
Global quality of life 56.7 (20.7) 50.0 0.0-100.0
Physical functioning 86.6 (16.7) 93.3 0.0-100.0
Role functioning 89.1 (19.3) 100.0 0.0-100.0
Emotional functioning 78.4 (18.4) 75.0 22.2-100.0
Cognitive functioning 77.0 (18.9) 83.3 0.0-100.0
Social functioning 78.8 (23.1) 83.3 0.0-100.0
Fatigue 27.3 (21.6) 33.3 0.0-100.0
Nausea/Vomiting 5.7 (12.3) 0.0 0.0-66.7
Pain 18.7 (21.6) 16.7 0.0-100.0
Dyspnoea 12.4 (18.6) 0.0 0.0-100.0
Insomnia 24.7 (25.6) 33.3 0.0-100.0
Appetite loss 13.0 (21.0) 0.0 0.0-100.0
Constipation 17.5 (23.6) 0.0 0.0-100.0
Diarrhoea 10.9 (17.4) 0.0 0.0-66.7
Financial problems 23.2 (28.1) 16.7 0.0-100.0
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire C30; SD: standard deviation.
1 77 31.8
2 45 18.6
3 20 8.3activity of daily life was interfered, 6 (2.5%) survivors
required tube feeding for severe difficulty when swallow-
ing, and 20 (8.3%) survivors presented remarkable neck
fibrosis, so regular rehabilitation was suggested.
Variables associated with QoL
In the one-factor model of GLM-MANOVA, the associ-
ation of each independent variable (including eight clin-
ical variables and five CTCAE variables) with the
dependent variables (fifteen scales of QLQ-C30) was in-
vestigated (Table 4). We observed that gender, education
years, RT technique, and survival years in the clinical
variables and all five of the CTCAE variables were sig-
nificantly (p <0.05) associated with the overall outcome
of QLQ-C30. In the multifactor model (backward exclu-
sion), those variables with p < 0.25 in one-factor model
were entered as independent variables; years of educa-
tion, RT technique, and survival years in the clinical
Table 4 The GLM-MANOVA model of the effects of the






Variable Wilk’s λ P value Wilk’s λ P value
Clinical variable
Age (≦40 v 41–60 v >60) 0.844 0.177 0.878 NS
Gender (Male v Female) 0.891 0.048 0.881 NS
Education years (≦6 yrs v 6-12 yrs
v >12 yrs)
0.779 0.004 0.766 0.003
Marital status (Without v with
partner)
0.922 0.285 – –
AJCC stage (I v II v III v IV) 0.765 0.088 0.876 NS
Radiotherapy technique
(Non-IMRT v IMRT)
0.806 <0.001 0.739 0.002
Chemotherapy (No v Yes) 0.894 0.058 0.957 NS
Survival years (5 ~ 7 yrs v 7-10 yrs
v >10 yrs)
0.795 0.012 0.795 0.021
CTCAE
Neuropathy (0 v 1 v 2 v 3) 0.650 <0.001 0.686 0.001
Hearing loss (0 v 1 v 2 v 3 + 4) 0.658 <0.001 0.713 0.02
Dysphagia (0 v 1 v 2 v 3) 0.702 0.002 0.755 NS
Xerostomia (0 v 1 v 2 v 3) 0.631 <0.001 0.697 0.003
Neck (0 v 1 v 2 + 3) 0.782 0.006 0.853 NS
GLM-MANOVA: general linear model multivariate analysis of variance; EORTC
QLQ-C30: European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire C30; CTCAE: Common Terminology Criteria for Adverse Events,
v4.0; AJCC: American Joint of Cancer Committee published in 2002; IMRT: intensity
modulated radiotherapy; NS: not significant; *The one factor model: only one
independent variable was entered into the model; **The multifactor model:
variables with p < 0.25 in one-factor model were entered as independent variables
in the model (Backward exclusion).
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in the CTCAE variables remained statistically significant.
CTCAE neuropathy and QoL outcome
The major causes of the 32 cases with symptomatic
(grade 2 and 3) CTCAE neuropathy were cranial neur-
opathy in 20 cases, including 17 hypoglossal palsy, two
brachial plexopathy and one optic neuropathy, temporal
lobe necrosis (n = 8), and ischaemic stroke related to
carotid artery stenosis (n = 4). A statistically significant
trend (p <0.05) was observed, indicating that NPC survi-
vors with more severe neuropathy had a worse outcome
on global QoL, all five of the functional scales, and the
five symptomatic scales (fatigue, nausea/vomiting, pain,
insomnia, and financial problems) (Table 5). In the case of
grade 2 neuropathy, a moderate to large impact (Cohen’s
D: 0.42–0.96) was observed on all scales of QLQ-C30. For
the 14 cases with grade 3 neuropathy, a large effect
(Cohen’s D: 0.90–1.38) was observed on global QoL, all
five functional scales, and the symptomatic scales of
fatigue and pain.CTCAE hearing loss and QoL outcome
A statistically significant trend (p <0.05) was observed,
indicating that those survivors with more severe CTCAE
hearing loss presented a worse outcome in global QoL,
all five functional scales, and six of the symptomatic
scales (fatigue, nausea/vomiting, pain, dyspnoea, appetite
loss, and financial problems) (Table 6). In the case of
grade 2 hearing loss, a moderate effect (Cohen’s D: 0.43–
0.68) was observed on global QoL, all five functional
scales, and four of the symptomatic scales of QLQ-C30.
For the 50 cases with grade 3 hearing loss, a large effect
(Cohen’s D: 0.81–0.94) was observed on global QoL and
three functional scales (physical, role, and cognitive
functioning).
CTCAE xerostomia and QoL outcome
A statistically significant trend (p <0.05) was also ob-
served, which revealed that those survivors with more
severe CTCAE xerostomia presented a worse outcome
in all of the QLQ-C30 scales (Table 7). In the 133 cases
with grade 2 xerostomia, a moderate to severe effect
(Cohen’s D: 0.57–1.48) was observed on global QoL, all
five functional scales, and five of the symptomatic scales
of QLQ-C30. There were only two cases with grade 3
xerostomia; however, a large effect (Cohen’s D: 1.63–
5.76) was observed in 14 scales (except insomnia) of
QLQ-C30.
Discussion
The primary endpoint in the current study is to answer
what radiation-induced late toxicities assessed by physi-
cians significantly affect the patient-reported QoL out-
come for NPC patients with long term survival. The
physician-rated quantitatively scoring morbidity systems
such as the Danish Head and Neck Cancer Group
(DAHANCA) and Radiation Therapy Oncology Group
(RTOG) systems have been found to be significantly cor-
related with general QoL domains of the EORTC QLQ-
C30 in HNC patients [6,11]. As far as we know, our study
is the first to use the CTCAE system to investigate the
association of late morbidity outcome with patient’s QoL.
Results of the multivariate analysis indicated that neur-
opathy, hearing loss, and xerostomia of CTCAE morbidity
scales had a statistically significant and clinically relevant
impact on the general QoL domains of QLQ-C30 for NPC
survivors.
Radiation-induced neuropathy is a chronic handicap,
usually appearing several years after RT. Tissue fibrosis/
necrosis or vessel occlusion may play an important role
[12]. The major causes of neuropathy in our cases in-
cluded cranial neuropathy, followed by temporal lobe ne-
crosis, and carotid artery stenosis. The occurrence of
cranial neuropathy for NPC patients increases with im-
proved long-term survival. In our cohort, 13.2% presented
Table 5 The relationship between the CTCAE grading of neuropathy and the scores of the individual EORTC QLQ-C30
scales and the effect size of the differences
CTCAE grading of neuropathy
Grade 0 (n = 196) Grade 1 (n = 14) Grade 2 (n = 18) Grade 3 (n = 14)
Mean (SD) Mean (SD) Cohen’s D ES Mean (SD) Cohen’s D ES Mean (SD) Cohen’s D ES p
Global quality of life 60 (18) 54 (23) 0.31 M 41 (22) 0.95 L 33 (23) 1.26 L <0.001
Physical functioning 89 (13) 88 (13) 0.13 S 76 (22) 0.75 M 61 (27) 1.33 L <0.001
Role functioning 91 (16) 92 (14) 0.00 S 80 (28) 0.53 M 60 (28) 1.38 L <0.001
Emotional functioning 81 (17) 82 (15) 0.04 S 65 (24) 0.77 M 61 (19) 1.10 L <0.001
Cognitive functioning 79 (18) 77 (14) 0.10 S 69 (22) 0.48 M 58 (25) 0.95 L 0.006
Social functioning 82 (21) 75 (13) 0.37 M 62 (29) 0.81 L 52 (26) 1.28 L <0.001
Fatigue 25 (20) 25 (16) 0.01 S 42 (27) 0.70 M 46 (21) 1.02 L 0.001
Nausea/Vomiting 5 (11) 4 (7) 0.12 S 10 (14) 0.42 M 15 (20) 0.65 M 0.008
Pain 16 (20) 17 (20) 0.04 S 37 (24) 0.96 L 37 (26) 0.90 L <0.001
Dyspnoea 11 (17) 8 (15) 0.22 S 22 (26) 0.47 M 21 (25) 0.47 M NS
Insomnia 22 (24) 23 (21) 0.04 S 41 (24) 0.76 M 40 (37) 0.58 M 0.006
Appetite loss 12 (20) 7 (14) 0.27 S 22 (26) 0.46 M 24 (33) 0.44 M NS
Constipation 17 (23) 13 (22) 0.17 S 28 (26) 0.45 M 21 (28) 0.18 S NS
Diarrhoea 10 (17) 6 (13) 0.31 M 19 (21) 0.44 M 14 (22) 0.21 S NS
Financial problems 20 (26) 24 (24) 0.16 S 46 (26) 0.84 L 40 (32) 0.71 M 0.001
Abbreviations: CTCAE: Common Terminology Criteria for Adverse Events, v4.0; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire C30; SD: standard deviation; Cohen’s D was calculated relative to grade 0; ES: effect size based on Cohen’s D; S: small; M: moderate;
L: large; NS: not significant.
Table 6 The relationship between the CTCAE grading of hearing loss and the scores of the individual EORTC QLQ-C30
scales and the effect size of the differences
CTCAE grading of hearing loss
Grade 0 (n = 87) Grade 1 (n = 32) Grade 2 (n = 73) Grade 3-4 (n = 50)
Mean (SD) Mean (SD) Cohen’s D ES Mean (SD) Cohen’s D ES Mean (SD) Cohen’s D ES p
Global quality of life 62 (20) 58 (18) 0.20 S 54 (21) 0.68 M 49 (21) 0.94 L <0.001
Physical functioning 91 (13) 91 (13) 0.04 S 86 (18) 0.55 M 77 (19) 0.92 L <0.001
Role functioning 92 (19) 92 (15) 0.02 S 90 (18) 0.52 M 81 (22) 0.84 L <0.001
Emotional functioning 84 (18) 78 (19) 0.33 S 77 (19) 0.47 M 73 (17) 0.64 M 0.005
Cognitive functioning 82 (17) 77 (19) 0.28 S 77 (17) 0.60 M 70 (22) 0.81 L <0.001
Social functioning 85 (21) 82 (23) 0.13 S 77 (21) 0.43 M 69 (25) 0.70 M <0.001
Fatigue 22 (19) 21 (18) 0.04 S 31 (23) 0.46 M 35 (22) 0.67 M <0.001
Nausea/Vomiting 2 (7) 7 (13) 0.51 M 8 (14) 0.53 M 8 (16) 0.48 M 0.007
Pain 15 (22) 13 (17) 0.11 S 22 (24) 0.32 S 25(19) 0.53 M 0.007
Dyspnoea 8 (14) 14 (17) 0.38 S 16 (23) 0.47 M 14 (19) 0.39 S 0.022
Insomnia 21 (25) 21 (26) 0.01 S 29 (27) 0.33 S 28 (24) 0.30 S NS
Appetite loss 8 (14) 11 (16) 0.25 S 16 (22) 0.44 M 19 (29) 0.51 M 0.009
Constipation 16 (20) 11 (16) 0.27 S 17 (24) 0.03 S 24 (31) 0.20 S NS
Diarrhoea 9 (16) 11 (18) 0.13 S 13 (17) 0.26 S 24 (31) 0.21 S NS
Financial problems 19 (27) 21 (25) 0.08 S 22 (23) 0.14 S 12 (19) 0.49 M 0.020
Abbreviations: CTCAE: Common Terminology Criteria for Adverse Events, v4.0; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire C30; SD: standard deviation; Cohen’s D was calculated relative to grade 0; ES: effect size based on Cohen’s D; S: small; M: moderate;
L: large; NS: not significant.
Tsai et al. BMC Cancer 2014, 14:856 Page 5 of 8
http://www.biomedcentral.com/1471-2407/14/856
Table 7 The relationship between the CTCAE grading of xerostomia and the scores of the individual EORTC QLQ-C30
scales and the effect size of the differences
CTCAE grading of xerostomia
Grade 0 (n = 77) Grade 1 (n = 100) Grade 2 (n = 133) Grade 3 (n = 2)
Mean (SD) Mean (SD) Cohen’s D ES Mean (SD) Cohen’s D ES Mean (SD) Cohen’s D ES p
Global quality of life 77 (12) 63 (18) 0.97 M 51 (22) 1.48 L 42 (12) 2.94 L <0.001
Physical functioning 98 (5) 91 (11) 0.79 M 83 (19) 1.10 L 70 (5) 5.76 L <0.001
Role functioning 95 (13) 95 (11) 0.02 S 84 (23) 0.58 M 67 (0) 3.21 L <0.001
Emotional functioning 82 (15) 86 (15) 0.28 S 73 (18) 0.57 M 50 (24) 1.63 L <0.001
Cognitive functioning 83 (17) 83 (17) 0.02 S 73 (19) 0.59 M 50 (24) 1.63 L <0.001
Social functioning 95 (13) 87 (17) 0.52 M 72 (25) 1.20 L 50 (24) 2.39 L <0.001
Fatigue 11 (16) 19 (186) 0.49 M 34 (22) 1.18 L 56 (16) 2.83 L <0.001
Nausea/Vomiting 2 (5) 3 (7) 0.51 M 10 (15) 0.77 M 33 (0) 2.65 L <0.001
Pain 5 (13) 9 (15) 0.33 S 26 (23) 1.14 L 50 (24) 2.39 L <0.001
Dyspnoea 10 (16) 8 (14) 0.12 S 16 (21) 0.34 S 33 (0) 2.08 L 0.008
Insomnia 29 (30) 18 (21) 0.42 M 30 (27) 0.03 S 50 (24) 0.79 M 0.002
Appetite loss 5 (13) 7 (14) 0.19 S 17 (23) 0.64 M 83 (24) 4.16 L <0.001
Constipation 14 (18) 14 (20) 0.12 S 19 (25) 0.23 S 83 (24) 3.31 L 0.032
Diarrhoea 5 (13) 7 (15) 0.19 S 13 (18) 0.54 M 50 (24) 2.39 L 0.003
Financial problems 5 (13) 17 (24) 0.65 M 28 (30) 1.03 L 50 (24) 2.39 L 0.002
Abbreviations: CTCAE: Common Terminology Criteria for Adverse Events, v4.0; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Qual-
ity of Life Questionnaire C30; SD: standard deviation; Cohen’s D was calculated relative to grade 0; ES: effect size based on Cohen’s D; S: small; M: moderate;
L: large.
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et al., the cumulative incidences of cranial neuropathy
were as high as 10.4%, 22.4%, 35.5%, and 44.5% at 5, 10,
15, and 20 years, respectively [13]. As it is progressive and
often irreversible, radiation-induced neuropathy is usually
a frightening development for patients. However, as far as
we know, the impact of neuropathy on the QoL for NPC
survivors has seldom been explored in the literature. Our
study highlighted the significance of radiation-induced
neuropathy in association with the QoL outcome for NPC
survivors, revealing that the greater the severity of neur-
opathy measured by physicians, the worse the outcome of
broad aspects of QoL reported by patients.
Radiation-induced otitis media can cause conductive
deafness, presenting with ear stuffiness, tinnitus, and hea-
ring loss. Hearing loss may be transient and begin as early
as 3 months after the completion of RT, but it can also be-
come chronic and progressive and last for a lifetime [14].
In our patients, the frequency of hearing loss was 50.4%,
second only to xerostomia. Despite the common inci-
dence, radiation-induced hearing loss is usually difficult to
treat, and the current methods are not always effective.
Many studies have demonstrated that hearing problems,
such as chronic otitis media, tinnitus, or hearing loss, sig-
nificantly deteriorated the physical or mental QoL status
of adolescents or elderly adults in the general population
[15,16]. As expected, hearing loss was a devastating prob-
lem for NPC survivors and like neuropathy the severity ofhearing loss had a significantly negative impact on QoL
domains.
Xerostomia rather than dysphagia was observed to have
a more pronounced impact on the overall QoL outcome
in our study. This result is in contrast to the report by
Lovell et al. [17]. In their study, they used the University
of Washington Quality-of-Life Questionnaire and the
Swallow Quality-of-Life Questionnaire to investigate the
impact of dysphagia on the QoL for NPC survivors. Of the
51 cases who responded, 43 (84%) had self-reported
dysphagia and those with dysphagia reported a signifi-
cantly lower QoL. Dysphagia is usually multifactorial and
strongly associated with xerostomia and it is difficult for
assessors to judge whether xerostomia or dysphagia would
impact more on patients’ QoL. In the CTCE v.4.0, it is not
possible to differentiate the distinct difference between
dysphagia and xerostomia, e.g. grade 2 dysphagia “symp-
tomatic and altered eating/swallowing”, which is similar to
grade 2 xerostomia “oral intake alteration, e.g. diets lim-
ited purees and/soft, moist foods”. Therefore, in clinical
practice, many patients were regarded simultaneously with
the same severity of dysphagia and xerostomia. Mean-
while, both grade 3 dysphagia and xerostomia in CTCAE
v.4.0 are defined as “tube feeding is indicated”. We believe
that low grade dysphagia might be xerostomia-related in
most cases and high grade can be attributed to the dys-
function of swallowing structures. As a result, we regarded
the six cases with tube feeding and tongue atrophy due to
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cases with tube feeding but without tongue atrophy as
grade 3 xerostomia.
Some reports have shown that radiation-induced dys-
phagia in HNC plays an important role in QoL domains
and have highlighted the importance of not only parotid
sparing by modern IMRT techniques, but also preserving
the pharyngeal muscles that are involved in swallowing
function during irradiation [18-20]. However, in the report
by Teguh et al., they observed that dysphagia was tumour
site-specific, and that NPC patients suffered from less dys-
phagia than oropharyngeal cancer patients did [18]. We
found that, in contrast to other anatomic sites of HNC,
NPC survivors presented some specific but common late
sequelae related to the irradiation field, such as otitis
media, hypothalamic-pituitary-thyroid dysfunction, and
neuropathy related from temporal lobe necrosis, cranial
nerve palsy, or carotid arterial stenosis, etc. [21-23]. Be-
sides parotid sparing for the prevention of xerostomia or
dysphagia, the modern conformal radiation technique
should place more emphasis on the anatomic structures
that are involved in these late complications, e.g. cochlea,
thyroid and pituitary gland, temporal lobe, and carotid
artery. Furthermore, regular examinations such as carotid
duplex scanning or evaluation of thyroid function for early
detection and possibly intervention of these potential late
complications should be kept in mind in routine clinical
practice especially for those with high risk factors and long
term survival [22,23].
This study has several limitations. First, no pre-
treatment QoL data were available in this cross-sectional
study and the post-treatment late toxicities assessed by
physicians were subjective. It was difficult to determine
whether the late toxicities after treatment were the result
of treatment or the result of the pre-existing cancer. Also,
about two thirds of our patients were treated with a com-
bination of chemotherapy, and we could not exclude the
morbidity being related to chemotherapy. Second, only
surviving patients receiving regular follow-up were en-
rolled, which might have caused selection bias. Third, the
study cohort included the evolved heterogeneous radio-
therapeutic components from 2D, 3D conformal to IMRT
techniques at different time periods and the dosimetric
data were not provided in the cohort; therefore, it was
difficult to establish the specific variables of the RT tech-
nique and survival years that might have confounded the
analysis.
Conclusions
To improve QoL outcome for NPC survivors, the devel-
opment of a modern radiotherapeutic technique should
not only focus on reduction of the dose to the salivary
glands, but also on anatomical structures that are in-
volved in neuropathy and hearing loss.Additional file
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